Streetbeat News

SNES

SenesTech, Inc.

https://www.senestech.com

Industry

Chemicals - Specialty

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Open

3.33

Mkt cap

3.1M

Volume

82K

High

3.45

P/E Ratio

0.03

52-wk high

9.80

Low

2.94

Div yield

N/A

52-wk low

1.90

SenesTech, Inc. has announced a significant shipment of its Evolve Rodent Birth Control product to a major warehousing and distribution company in the Midwest, marking its expansion into this sector.

Portfolio Pulse from

February 18, 2025 | 2:00 pm

SenesTech, Inc. (Nasdaq: SNES) is expanding its global presence by entering the Indian rodent pest control market through a partnership with SMark. This move is part of their strategy to promote humane pest control solutions globally.

Portfolio Pulse from

February 04, 2025 | 4:45 pm

Baltimore has adopted SenesTech's Evolve™ rodent birth control as part of its pest management strategy to control rodent overpopulation. This move is seen as a humane and effective solution to Baltimore's rodent issues.

Portfolio Pulse from

January 21, 2025 | 1:15 pm

SenesTech, Inc. has announced the appointment of Joshua M. Moss to its Board of Directors. This move is part of the company's ongoing efforts to strengthen its leadership team.

Portfolio Pulse from

January 10, 2025 | 9:30 pm

SenesTech, Inc. reported its third quarter 2024 financial results, highlighting a 51% increase in revenue to $1.4 million for the first nine months of 2024 compared to the same period in 2023.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

SenesTech, Inc. has expanded the distribution of its rodent birth control products, Evolve™ Rat and Evolve™ Mouse, by launching them on Walmart Marketplace. This move significantly increases the market reach of SenesTech's products.

Portfolio Pulse from

November 12, 2024 | 2:15 pm

SenesTech, Inc. (NASDAQ: SNES) will release its Q3 2024 financial results on November 12, 2024, after market close, followed by a conference call at 5:00 pm ET to discuss the results.

Portfolio Pulse from

November 05, 2024 | 9:30 pm

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include SenesTech, Venus Concept, and AtriCure, while Tyra Biosciences, DaVita, and 10x Genomics were among the losers. AtriCure, DaVita, and 10x Genomics released their Q3 earnings.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 8:31 pm

SenesTech (NASDAQ:SNES) reported Q2 2024 GAAP EPS of $(3.08), beating the estimate of $(3.20). However, sales of $459,000 missed the $485,000 estimate. Sales increased by 50.49% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

SenesTech (NYSE:SNES) has seen a significant rise in its short interest, with 82.08% of its float sold short. This is much higher than its peers' average of 6.89%. It would take traders 9.96 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.